Fast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times

  • 📰 SFBusinessTimes
  • ⏱ Reading Time:
  • 43 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 68%

대한민국 뉴스 뉴스

대한민국 최근 뉴스,대한민국 헤드 라인

Why $ACET is moving quickly with its cell therapy against non-Hodgkin's lymphoma — and taking more space

As Adicet Bio Inc. pushed forward on the path to a potentially pivotal clinical trial, one thing was clear to President and CEOAdicet , which late last year had 87 employees, has hired 44 people since the start of this year as the company tries to prove that its cancer cell therapy not only works but has a durable response in patients.

In June, when Adicet inked the deal for the additional square footage, it had eight patients who could be evaluated and 75% of those had had complete responses, when all detectable cancer is gone. When data came back from the second and third doses of the drug, which is partnered with Regeneron Pharmaceuticals Inc. , 80% of patients had reached that point.

About 80,000 people a year in the United States are diagnosed with NHL. It is treated today with chemotherapy, radiation therapy, bone marrow transplants or other therapies, including other emerging cell therapies. Gamma-delta cells may be the under-appreciated instrument in the fast-moving world of cell therapy development, but while they aren't dangerous, their efficacy and durability isn't proved. But Schor said Adicet is progressing toward that goal.

이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 78. in KR
 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.

대한민국 최근 뉴스, 대한민국 헤드 라인